Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 10, 2008. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding changes in share interests under the Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event.
Material Changes
The only material change reported is an increase in the share interest of Dr. D. Pulman. This change resulted from the re-investment of dividends paid on October 9, 2008, under the Annual Investment Plan feature. The transaction occurred at a price of $35.41 per ADR, resulting in an interest of 33.74 units.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: October 10, 2008 (Notification date); October 9, 2008 (Dividend payment date).
- Individual Involved: Dr. D. Pulman.
- Transaction Type: Increase in Ordinary share ADR interest via dividend re-investment.
- Price per ADR: $35.41.
- Resulting Interest: 33.74.